These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 32569729)
1. Clinical and genomic characterization of neutral tumor evolution in Head and Neck Squamous Cell Carcinoma. Li R; Dong J; Zhang H; Zhao Q; Li X; Liu X; Ye Y; Deng S; Lin D; Zheng J; Zuo Z Genomics; 2020 Sep; 112(5):3448-3454. PubMed ID: 32569729 [TBL] [Abstract][Full Text] [Related]
2. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791 [No Abstract] [Full Text] [Related]
3. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma. Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115 [TBL] [Abstract][Full Text] [Related]
4. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer. Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036 [TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma. Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580 [TBL] [Abstract][Full Text] [Related]
6. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma. Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553 [TBL] [Abstract][Full Text] [Related]
7. An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma. Chen Y; Luo TQ; Xu SS; Chen CY; Sun Y; Lin L; Mao YP Cancer Med; 2021 Apr; 10(7):2268-2285. PubMed ID: 33660378 [TBL] [Abstract][Full Text] [Related]
8. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma. Zhang F; Liu Y; Yang Y; Yang K BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731 [TBL] [Abstract][Full Text] [Related]
9. A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma. Chen L; Cai Z; Lyu K; Cai Z; Lei W Bioengineered; 2021 Dec; 12(1):2311-2325. PubMed ID: 34167440 [TBL] [Abstract][Full Text] [Related]
10. High Abundance of Intratumoral γδ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. Lu H; Dai W; Guo J; Wang D; Wen S; Yang L; Lin D; Xie W; Wen L; Fang J; Wang Z Front Immunol; 2020; 11():573920. PubMed ID: 33101298 [TBL] [Abstract][Full Text] [Related]
11. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. Chen Y; Li ZY; Zhou GQ; Sun Y Clin Cancer Res; 2021 Jan; 27(1):330-341. PubMed ID: 33097495 [TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets. Shen Y; Liu J; Zhang L; Dong S; Zhang J; Liu Y; Zhou H; Dong W Biomed Res Int; 2019; 2019():7376034. PubMed ID: 31485443 [TBL] [Abstract][Full Text] [Related]
13. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas. Ma B; Li H; Qiao J; Meng T; Yu R Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111959 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of ubiquitin-proteasome system genes related to prognosis and immunosuppression in head and neck squamous cell carcinoma. Wang J; Li J; Zhang L; Qin Y; Zhang F; Hu R; Chen H; Tian Y; Liu Z; Tian Y; Zhang X Aging (Albany NY); 2021 Aug; 13(16):20277-20301. PubMed ID: 34398824 [TBL] [Abstract][Full Text] [Related]
15. A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma. Fang R; Iqbal M; Chen L; Liao J; Luo J; Wei F; Wen W; Sun W Aging (Albany NY); 2021 Apr; 13(8):11507-11527. PubMed ID: 33867351 [TBL] [Abstract][Full Text] [Related]
16. Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods. Jin Y; Yang Y Mol Genet Genomic Med; 2019 Aug; 7(8):e857. PubMed ID: 31304688 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727 [TBL] [Abstract][Full Text] [Related]
18. RUVBL1 is an amplified epigenetic factor promoting proliferation and inhibiting differentiation program in head and neck squamous cancers. Lin D; Lin B; Bhanot H; Riou R; Abt NB; Rajagopal J; Saladi SV Oral Oncol; 2020 Dec; 111():104930. PubMed ID: 32745900 [TBL] [Abstract][Full Text] [Related]
19. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626 [TBL] [Abstract][Full Text] [Related]
20. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I; Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]